Overview

A Phase 2 Study of ASP1585 in Chronic Kidney Disease Patients With Hyperphosphatemia on Hemodialysis

Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
To evaluate the superiority to placebo, dose-responsibility and safety.
Phase:
Phase 2
Details
Lead Sponsor:
Astellas Pharma Inc
Treatments:
Sevelamer